EnClear Therapies


EnClear Therapies aims to improve and extend the lives of patients suffering from CNS diseases through precision dosing. They are building an integrated neurotechnology business utilizing their proprietary EnTrega CSF Platform to create patient-focused opportunities, initially launching into neuro-oncology and expanding into neurodegenerative, lysosomal storage, and autoimmune diseases through partnerships.

Industries

biotechnology
therapeutics

Nr. of Employees

small (1-50)

EnClear Therapies

Cambridge, Massachusetts, United States, North America


Products

CSF delivery and monitoring platform (in development)

A platform that provides controlled, continuous, and personalized delivery of therapeutics via CSF combined with monitoring capabilities and integrated ML/AI for dosing optimization; intended to improve CNS distribution and enable outpatient administration.


Services

Partnerships for modality development and dose optimization

Collaborative development agreements to apply CSF delivery and monitoring to externally developed therapeutics (small molecules, ASOs, AAVs, siRNAs, enzyme therapies) and to optimize dosing profiles.

Preclinical evaluation of CNS distribution and delivery

Preclinical studies and testing to characterize CNS drug distribution and compare CSF-based delivery to standard intrathecal/intraventricular approaches.

Expertise Areas

  • CSF-based drug delivery
  • Precision dosing and personalized CNS therapeutics
  • Neuro-oncology (leptomeningeal carcinomatosis)
  • Preclinical CNS pharmacokinetics and biodistribution
  • Show More (4)

Key Technologies

  • CSF delivery systems
  • Closed-loop control systems
  • Machine learning / AI-driven dosing optimization
  • Intrathecal and intraventricular infusion techniques
  • Show More (3)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.